Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Tim, Grob"'
Autor:
Christian M. Vonk, Emma L. Boertjes, Francois G. Kavelaars, Melissa Rijken, Jolinda M. L. Konijnenburg, Roxanne E. Cromwell, Bob Löwenberg, Tim Grob, Peter J. M. Valk
Publikováno v:
HemaSphere, Vol 8, Iss 8, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/e4ace97ccecf4ac7a3b83065bfbd9adb
Autor:
Monica Hellesøy, Caroline Engen, Tim Grob, Bob Löwenberg, Peter J. M. Valk, Bjørn T. Gjertsen
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2285-2299 (2021)
Incidence, molecular presentation and outcome of acute myeloid leukaemia (AML) are influenced by sex, but little attention has been directed at untangling sex‐related molecular and phenotypic differences between female and male patients. While incr
Externí odkaz:
https://doaj.org/article/8697ddee894146828c0fad733a7ea5f9
Autor:
Caroline Engen, Monica Hellesøy, Tim Grob, Adil Al Hinai, Atle Brendehaug, Line Wergeland, Siv Lise Bedringaas, Randi Hovland, Peter J. M. Valk, Bjørn T. Gjertsen
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2300-2317 (2021)
Recurrent somatic internal tandem duplications (ITD) in the FMS‐like tyrosine kinase 3 (FLT3) gene characterise approximately one third of patients with acute myeloid leukaemia (AML), and FLT3‐ITD mutation status guides risk‐adapted treatment s
Externí odkaz:
https://doaj.org/article/5c847808f7ca4069b952cc2692905f06
Autor:
Tim Grob, Mathijs A. Sanders, Christian M. Vonk, Franҫois G. Kavelaars, Melissa Rijken, Diana W. Hanekamp, Patrycja L. Gradowska, Jacqueline Cloos, Yngvar Fløisand, Marinus van Marwijk Kooy, Markus G. Manz, Gert J. Ossenkoppele, Lidwine W. Tick, Violaine Havelange, Bob Löwenberg, Mojca Jongen-Lavrencic, Peter J.M. Valk
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(4):JCO2200715, 756-765. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(4), 756-765. American Society of Clinical Oncology
Grob, T, Sanders, M A, Vonk, C M, Kavelaars, F G, Rijken, M, Hanekamp, D W, Gradowska, P L, Cloos, J, Fløisand, Y, van Marwijk Kooy, M, Manz, M G, Ossenkoppele, G J, Tick, L W, Havelange, V, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2023, ' Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 41, no. 4, pp. 756-765 . https://doi.org/10.1200/JCO.22.00715, https://doi.org/10.1200/JCO.22.00715
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(4), 756-765. American Society of Clinical Oncology
Grob, T, Sanders, M A, Vonk, C M, Kavelaars, F G, Rijken, M, Hanekamp, D W, Gradowska, P L, Cloos, J, Fløisand, Y, van Marwijk Kooy, M, Manz, M G, Ossenkoppele, G J, Tick, L W, Havelange, V, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2023, ' Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 41, no. 4, pp. 756-765 . https://doi.org/10.1200/JCO.22.00715, https://doi.org/10.1200/JCO.22.00715
PURPOSE The applicability of FLT3-internal tandem duplications ( FLT3-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential ins
Autor:
Adil S.A. Al Hinai, Marta Pratcorona, Tim Grob, François G. Kavelaars, Elena Bussaglia, Mathijs A. Sanders, Josep Nomdedeu, Peter J.M. Valk
Publikováno v:
HemaSphere, Vol 3, Iss 2 (2019)
Externí odkaz:
https://doaj.org/article/a40cb19e521949a8ba658710856ed39e
Autor:
Tim Grob, Adil S. A. Al Hinai, Mathijs A. Sanders, François G. Kavelaars, Melissa Rijken, Patrycja L. Gradowska, Bart J. Biemond, Dimitri A. Breems, Johan Maertens, Marinus van Marwijk Kooy, Thomas Pabst, Okke de Weerdt, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Gerwin A. Huls, Jan J. Cornelissen, H. Berna Beverloo, Bob Löwenberg, Mojca Jongen-Lavrencic, Peter J. M. Valk
Publikováno v:
Blood, 139(15), 2347-2354. AMER SOC HEMATOLOGY
Blood, 139(15), 2347-2354. American Society of Hematology
Grob, T, Al Hinai, A S A, Sanders, M A, Kavelaars, F G, Rijken, M, Gradowska, P L, Biemond, B J, Breems, D A, Maertens, J, van Marwijk Kooy, M, Pabst, T, de Weerdt, O, Ossenkoppele, G J, van de Loosdrecht, A A, Huls, G A, Cornelissen, J J, Beverloo, H B, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2022, ' Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome ', Blood, vol. 139, no. 15, pp. 2347-2354 . https://doi.org/10.1182/blood.2021014472
Blood, 139(15), 2347-2354. American Society of Hematology
Grob, T, Al Hinai, A S A, Sanders, M A, Kavelaars, F G, Rijken, M, Gradowska, P L, Biemond, B J, Breems, D A, Maertens, J, van Marwijk Kooy, M, Pabst, T, de Weerdt, O, Ossenkoppele, G J, van de Loosdrecht, A A, Huls, G A, Cornelissen, J J, Beverloo, H B, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2022, ' Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome ', Blood, vol. 139, no. 15, pp. 2347-2354 . https://doi.org/10.1182/blood.2021014472
Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and myelodysplastic syndrome with excess of blast (MDS-EB) precludes the exact assessment of prognostic impact for individual patients. We performed in-depth clinical and molec
Autor:
Line Wergeland, Siv Lise Bedringaas, Peter J. M. Valk, Adil Al Hinai, Atle Brendehaug, Monica Hellesøy, Caroline Engen, Tim Grob, Bjørn Tore Gjertsen, Randi Hovland
Publikováno v:
Molecular Oncology, 15(9), 2300-2317. John Wiley & Sons Ltd.
Molecular Oncology
Molecular Oncology, Vol 15, Iss 9, Pp 2300-2317 (2021)
Molecular Oncology
Molecular Oncology, Vol 15, Iss 9, Pp 2300-2317 (2021)
Recurrent somatic internal tandem duplications (ITD) in the FMS‐like tyrosine kinase 3 (FLT3) gene characterise approximately one third of patients with acute myeloid leukaemia (AML), and FLT3‐ITD mutation status guides risk‐adapted treatment s
Autor:
Tim, Grob, Mathijs A, Sanders, Christian M, Vonk, Franҫois G, Kavelaars, Melissa, Rijken, Diana W, Hanekamp, Patrycja L, Gradowska, Jacqueline, Cloos, Yngvar, Fløisand, Marinus, van Marwijk Kooy, Markus G, Manz, Gert J, Ossenkoppele, Lidwine W, Tick, Violaine, Havelange, Bob, Löwenberg, Mojca, Jongen-Lavrencic, Peter J M, Valk
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
The applicability ofIn 161 patients with de novoNGS-basedNGS-based detection of
Autor:
Johan Maertens, Annoek E.C. Broers, Yvette van Norden, Mojca Jongen-Lavrencic, Gert J. Ossenkoppele, Michel van Gelder, Jan J. Cornelissen, Wendelien Zeijlemaker, Burak Kalin, Ellen Meijer, Dimitri Breems, Eric Braakman, Tim Grob
Publikováno v:
BLOOD ADVANCES, 4(18), 4430-4437. American Society of Hematology
Blood advances, 4(18), 4430-4437. American Society of Hematology
Kalin, B, van Norden, Y, van Gelder, M, Breems, D, Maertens, J, Jongen-Lavrencic, M, Broers, A E C, Braakman, E, Grob, T, Zeijlemaker, W, Ossenkoppele, G J, Meijer, E & Cornelissen, J J 2020, ' Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation ', BLOOD ADVANCES, vol. 4, no. 18, pp. 4430-4437 . https://doi.org/10.1182/BLOODADVANCES.2020002074
Blood Adv
Blood advances, 4(18), 4430-4437. The American Society of Hematology
Blood advances, 4(18), 4430-4437. American Society of Hematology
Kalin, B, van Norden, Y, van Gelder, M, Breems, D, Maertens, J, Jongen-Lavrencic, M, Broers, A E C, Braakman, E, Grob, T, Zeijlemaker, W, Ossenkoppele, G J, Meijer, E & Cornelissen, J J 2020, ' Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation ', BLOOD ADVANCES, vol. 4, no. 18, pp. 4430-4437 . https://doi.org/10.1182/BLOODADVANCES.2020002074
Blood Adv
Blood advances, 4(18), 4430-4437. The American Society of Hematology
Outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is adversely affected by relapse to a considerable degree. To exploit the graft-versus-leukemia effect more effectively, we assessed the feasibility of early initiation of e
Autor:
Tim Grob, Annelieke Zeilemaker, Melissa Rijken, Kirsten van Lom, Claudia A.J. Erpelinck-Verschueren, Mathijs A. Sanders, François G. Kavelaars, Peter J. M. Valk, Adil S.A. Al Hinai, Kirsten J. Gussinklo
Publikováno v:
Leukemia, 34(8), 2220-2224. Nature Publishing Group
Acute myeloid leukemia (AML) is a heterogeneous disease with a great variety of somatic driver mutations. Each AML carries specific (combinations of) acquired mutations, which enables minimal residual disease (MRD) detection in virtually every patien